AR072174A1 - Combinaciones que comprenden inhibidores de dhodh (dihidroorotato deshidrogenasa) y metotrexato. uso. producto. kit. metodo. - Google Patents
Combinaciones que comprenden inhibidores de dhodh (dihidroorotato deshidrogenasa) y metotrexato. uso. producto. kit. metodo.Info
- Publication number
- AR072174A1 AR072174A1 ARP090102209A ARP090102209A AR072174A1 AR 072174 A1 AR072174 A1 AR 072174A1 AR P090102209 A ARP090102209 A AR P090102209A AR P090102209 A ARP090102209 A AR P090102209A AR 072174 A1 AR072174 A1 AR 072174A1
- Authority
- AR
- Argentina
- Prior art keywords
- groups
- substituents selected
- optionally substituted
- halogen
- hydroxy groups
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Una combinacion que comprende (a) metotrexato y (b) un inhibidor de DHODH (dihidroorotato deshidrogenasa) no hepatotoxico. Reivindicacion 3: Una combinacion segun la reivindicacion 1 o 2, donde el inhibidor de DHODH (b) es un compuesto de formula (1) en la que uno de los grupos G1 representa un tomo de nitrogeno o un grupo CRc y el otro representa un grupo CRc; G2 representa un tomo de nitrogeno o un grupo CRd; R1 representa un grupo seleccionado de tomos de hidrogeno, halogeno, grupos alquilo C1-4 que pueden estar opcionalmente sustituidos con 1, 2 o 3 sustituyentes seleccionados de tomos de halogeno y grupos hidroxi, y grupos cicloalquilo C3-8 que pueden estar opcionalmente sustituidos con 1, 2 o 3 sustituyentes seleccionados de tomos de halogeno y grupos hidroxi; R2 representa un grupo seleccionado de tomos de hidrogeno, halogeno, grupos hidroxilo, grupos alquilo C1-4 que pueden estar opcionalmente sustituidos con 1, 2 o 3 sustituyentes seleccionados de tomos de halogeno y grupos hidroxi, grupos alcoxi C1-4 que pueden estar opcionalmente sustituidos con 1, 2 o 3 sustituyentes seleccionados de tomos de halogeno y grupos hidroxi, y grupos cicloalquilo C3-8 que pueden estar opcionalmente sustituidos o con 1, 2 o 3 sustituyentes seleccionados de tomos de halogeno y grupos hidroxi; Ra, Rb y Rc independientemente representan grupos seleccionados de tomos de hidrogeno, halogeno, grupos alquilo C1-4 que pueden estar opcionalmente sustituidos con 1, 2 o 3 sustituyentes seleccionados de tomos de halogeno y grupos hidroxi, y grupos alcoxi C1-4 que pueden estar opcionalmente sustituidos con 1, 2 o 3 sustituyentes seleccionados de tomos de halogeno y grupos hidroxi; Rd representa un grupo seleccionado de tomos de hidrogeno, halogeno, grupos hidroxilo, grupos alquilo C1-4 que pueden estar opcionalmente sustituidos con 1, 2 o 3 sustituyentes seleccionados de tomos de halogeno y grupos hidroxi, y grupos alcoxi C1-4 que pueden estar opcionalmente sustituidos con 1, 2 o 3 sustituyentes seleccionados de tomos de halogeno y grupos hidroxi, y grupos cicloalcoxi C3-8 que pueden estar opcionalmente sustituidos con 1, 2 o 3 sustituyentes seleccionados de tomos de halogeno y grupos hidroxi, uno de los grupos G3 y G4 es un tomo de nitrogeno y el otro es un grupo CH, M es un tomo de hidrogeno o un cation farmaceuticamente aceptable con la condicion de que, cuando al menos uno de los grupos Ra y Rb representa un tomo de hidrogeno y G2 es un grupo CRd, entonces Rd representa un grupo seleccionado de grupos alcoxi C1-4 que pueden estar opcionalmente sustituidos con 1, 2 o 3 sustituyentes seleccionados de tomos de halogeno y grupos hidroxi, grupos cicloalcoxi C3-8 que pueden estar opcionalmente sustituidos con 1, 2 o 3 sustituyentes seleccionados de tomos de halogeno y grupos hidroxi; y sus sales y N-oxidos farmaceuticamente aceptables. Reivindicacion 26: Una combinacion segun la reivindicacion 3 o 4 donde el inhibidor de DHODH es cido 2-(3'-etoxi-3,5-difluorobifenil-4-ilamino)nicot¡nico o una sal o N-oxido farmaceuticamente aceptable del mismo. Reivindicacion 27: Una combinacion segun la reivindicacion 3 o 4 donde el inhibidor de DHODH es cido 2-(3,5-difluoro-3'-metoxibifenil-4-ilamino)nicot¡nico o una sal o N-oxido farmaceuticamente aceptable del mismo. Reivindicacion 28: Una combinacion segun la reivindicacion 3 o 4 donde el inhibidor de DHODH es cido 2-(3'-ciclopropoxi-3,5-difluorobifenil-4-ilamino)nicot¡nico o una sal o N-oxido farmaceuticamente aceptable del mismo. Reivindicacion 29: Una combinacion segun la reivindicacion 3 o 4 donde el inhibidor de DHOOH es cido 2-(3,5-difluoro-3'-metoxibifenil-4-ilamino)-5-metiInicot¡nico o una sal o N-oxido farmaceuticamente aceptable del mismo. Reivindicacion 31: Una combinacion segun una cualquiera de las reivindicaciones precedentes, que comprende adem s (c) otro compuesto seleccionado de: (i) Anticuerpos monoclonales anti-TNF-alfa tales como Infliximab, Certolizumab pegol, Golimumab, Adalimumab y AME-527 de Applied Molecular Evolution; (ii) Antagonistas de TNF-alfa tales como Etanercept, Lenercept, Onercept y Pegsunercept; (iii) Inhibidores de Calcineurina (PP-2B) / Inhibidores de la expresion de INS tales como ciclosporina A, Tacrolimus y ISA-247 de Isotechnika; (iv) Antagonistas del receptor IL-1 tales como Anakinra y AMG-719 de Amgen; (v) Anticuerpos monoclonales anti-CD20 tales como Rituximab, Ofatumumab, Ocrelizumab y TRU-015 de Trubion Pharmaceuticals; (vi) Inhibidores de p38 tales como AMG-548 (de Amgen), ARRY-797 (de Array Biopharma), edisilato de clormetiazol, Doramapimod, PS-540446 (de BMS), SB-203580, SB-242235, SB-235699, SB-281832, SB-681323, SB-856553 (todos de GlaxoSmithKline), KC-706 (de Kemia), LEO-1606, LEO-15520 (todos de Leo), SC-80036, SD-06 (todos de Pfizer), RWJ-67657 (de R. W. Johnson), RO-3201195, RO-4402257 (todos de Roche), AVE-9940 (de Aventis), SCIO-323, SCIO-469 (todos de Scios), TA-5493 (de Tanabe Seiyaku), y VX-745 y VX-702 (todos de Vertex); (vii) Inhibidores de la activacion de NF-kappaB (NFKB) tales como Sulfasalazina e Iguratimod; (viii) Otro inhibidor de dihidrofolato reductasa (DHFR) tal como Aminopterina y CH-1504 de Chelsea; (ix) Inhibidores de Janus quinasa (JAK), tales como CP-690, 550 de Pfizer y INCB-18424, de Incyte; (x) Inhibidor de MEK, tal como ARRY-162 de Array; (xi) Agonistas de los receptores de 1-fosfato de esfingosina, tales como fingolimod (Novartis); (xii) Interferones que comprenden Interferon beta la tal como Avonex de Biogen ldec, CinnoVex de CinnaGen y Rebif de EMD Serono, e Interferon beta 1b tal como Betaferon de Schering y Betaseron de Berlex; (xiii) Inmunomoduladores tales como BG-12 (derivado del cido fum rico) de Biogen Idec/Fumapharm AG, (xiv) Inhibidores de la adenosina aminohidrolasa tales como Cladribina de Merck Serono. Reivindicacion 32: Uso de (a) metotrexato y (b) un inhibidor de DHODH como se define en una cualquiera de las reivindicaciones 1 a 29 para la preparacion de un medicamento para uso simult neo, separado o secuencial en el tratamiento de un estado patologico o enfermedad susceptible a mejorar por inhibicion de deshidroorotato deshidrogenasa. Reivindicacion 33: Uso segun la reivindicacion 32, donde el estado patologico o enfermedad se selecciona de artritis reumatoide, artritis psori tica, espondilitis anquilosante, esclerosis multiple, granulomatosis de Wegener, lupus eritematoso sistemico, psoriasis y sarcoidosis. Reivindicacion 49: Un inhibidor de DHODH como se ha definido en una cualquiera de las reivindicaciones 1 a 29, para uso en el tratamiento de un paciente humano o animal que padece un estado patologico o enfermedad, como se ha definido en la reivindicacion 32 o 33, donde el paciente humano o animal padece o es susceptible de padecer insuficiencia hep tica o un estado que se agravar¡a por hepatotoxicidad, como se ha definido en la reivindicacion 43 o 44.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08382022A EP2135610A1 (en) | 2008-06-20 | 2008-06-20 | Combination comprising DHODH inhibitors and methotrexate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR072174A1 true AR072174A1 (es) | 2010-08-11 |
Family
ID=39930498
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090102209A AR072174A1 (es) | 2008-06-20 | 2009-06-18 | Combinaciones que comprenden inhibidores de dhodh (dihidroorotato deshidrogenasa) y metotrexato. uso. producto. kit. metodo. |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US8865728B2 (es) |
| EP (2) | EP2135610A1 (es) |
| JP (1) | JP5507551B2 (es) |
| KR (1) | KR101675601B1 (es) |
| CN (1) | CN102065866B (es) |
| AR (1) | AR072174A1 (es) |
| AU (1) | AU2009259625B2 (es) |
| BR (1) | BRPI0909995A2 (es) |
| CA (1) | CA2728976C (es) |
| CL (1) | CL2010001359A1 (es) |
| CO (1) | CO6321267A2 (es) |
| CY (1) | CY1119643T1 (es) |
| DK (1) | DK2296663T3 (es) |
| EA (1) | EA020193B1 (es) |
| ES (1) | ES2641168T3 (es) |
| HR (1) | HRP20171667T1 (es) |
| HU (1) | HUE036639T2 (es) |
| IL (1) | IL209267A (es) |
| LT (1) | LT2296663T (es) |
| ME (1) | ME02903B (es) |
| MX (1) | MX2010013409A (es) |
| MY (1) | MY155249A (es) |
| NO (1) | NO2296663T3 (es) |
| NZ (1) | NZ589089A (es) |
| PE (1) | PE20110149A1 (es) |
| PL (1) | PL2296663T3 (es) |
| PT (1) | PT2296663T (es) |
| RS (1) | RS56584B1 (es) |
| SG (2) | SG10201609515RA (es) |
| SI (1) | SI2296663T1 (es) |
| TW (1) | TWI440462B (es) |
| UA (1) | UA114388C2 (es) |
| UY (1) | UY31897A1 (es) |
| WO (1) | WO2009153043A1 (es) |
| ZA (1) | ZA201008041B (es) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2319596B1 (es) * | 2006-12-22 | 2010-02-08 | Laboratorios Almirall S.A. | Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico. |
| UY31272A1 (es) | 2007-08-10 | 2009-01-30 | Almirall Lab | Nuevos derivados de ácido azabifenilaminobenzoico |
| EA201100605A1 (ru) * | 2008-11-07 | 2012-02-28 | 4ЭсЦэ АГ | Комбинированная терапия, включающая ингибитор dhodh и метотрексат, для лечения аутоиммунного заболевания |
| EP2210615A1 (en) * | 2009-01-21 | 2010-07-28 | Almirall, S.A. | Combinations comprising methotrexate and DHODH inhibitors |
| EP2239256A1 (en) | 2009-03-13 | 2010-10-13 | Almirall, S.A. | Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor |
| EP2314577A1 (en) | 2009-10-16 | 2011-04-27 | Almirall, S.A. | Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid |
| US8686048B2 (en) | 2010-05-06 | 2014-04-01 | Rhizen Pharmaceuticals Sa | Immunomodulator and anti-inflammatory compounds |
| EP2457900A1 (en) | 2010-11-25 | 2012-05-30 | Almirall, S.A. | New pyrazole derivatives having CRTh2 antagonistic behaviour |
| US20140031383A1 (en) | 2011-02-08 | 2014-01-30 | Dana-Farber Cancer Institute, Inc. | Methods for treatment of melanoma |
| EP2518070A1 (en) | 2011-04-29 | 2012-10-31 | Almirall, S.A. | Pyrrolotriazinone derivatives as PI3K inhibitors |
| EP2518071A1 (en) | 2011-04-29 | 2012-10-31 | Almirall, S.A. | Imidazopyridine derivatives as PI3K inhibitors |
| EP2526945A1 (en) | 2011-05-25 | 2012-11-28 | Almirall, S.A. | New CRTH2 Antagonists |
| EP2548863A1 (en) | 2011-07-18 | 2013-01-23 | Almirall, S.A. | New CRTh2 antagonists. |
| EP2548876A1 (en) | 2011-07-18 | 2013-01-23 | Almirall, S.A. | New CRTh2 antagonists |
| CN103826624A (zh) * | 2011-08-30 | 2014-05-28 | 富山化学工业株式会社 | 类风湿性关节炎等自身免疫疾病的处置的改善方法 |
| EP2594271A1 (en) * | 2011-11-21 | 2013-05-22 | Almirall, S.A. | 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid for the treatment of psoriasis. |
| WO2014060431A1 (en) | 2012-10-16 | 2014-04-24 | Almirall, S.A. | Pyrrolotriazinone derivatives as pi3k inhibitors |
| AR094797A1 (es) | 2013-02-15 | 2015-08-26 | Almirall Sa | Derivados de pirrolotriazina como inhibidores de pi3k |
| CN103315985A (zh) * | 2013-05-16 | 2013-09-25 | 南京市鼓楼医院 | Fingolimod在制备抑制肝癌肝内转移药物中的应用 |
| WO2017075559A1 (en) * | 2015-10-30 | 2017-05-04 | E. I. Du Pont De Nemours And Company | Dihydroorotate dehydrogenase inhibitor compositions effective as herbicides |
| WO2018157843A1 (zh) * | 2017-03-02 | 2018-09-07 | 中国科学院上海药物研究所 | 2-(取代苯杂基)芳香甲酸类fto抑制剂，其制备方法及其应用 |
| WO2019012030A1 (en) | 2017-07-13 | 2019-01-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | DHODH INHIBITOR AND CHK1 INHIBITOR FOR THE TREATMENT OF CANCER |
| US20220227720A1 (en) | 2019-05-07 | 2022-07-21 | Universitat Hamburg | Dhodh inhibitors and their use as antiviral agents |
| EP4228640A1 (en) * | 2020-10-15 | 2023-08-23 | ASLAN Pharmaceuticals Pte Ltd | Treatment of autoimmune diseases with a dihydroorotate hehydrogenase (dhodh) inhibitor |
| EP4119138A1 (en) | 2021-07-12 | 2023-01-18 | Universität Hamburg | Dhodh inhibitors and their use as antiviral agents |
| WO2023204754A1 (en) * | 2022-04-21 | 2023-10-26 | Aslan Pharmaceuticals Pte Ltd | Treatment of autoimmune skin disease |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL122494A (en) | 1995-06-21 | 2001-08-08 | Asta Medica Ag | A cartridge for pharmaceutical powder with a measuring device and an integral inhaler for powdered medicines |
| DE19547648A1 (de) | 1995-12-20 | 1997-06-26 | Hoechst Ag | Zubereitung, enthaltend High Density Lipoproteine und Crotonsäureamidderivate |
| DE19610955A1 (de) | 1996-03-20 | 1997-09-25 | Hoechst Ag | Kombinationspräparat, enthaltend 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)- anilid und N-(4-Trifluormethylphenyl)-2-cyan-3- hydroxycrotonsäureamid |
| GB9804343D0 (en) | 1998-02-27 | 1998-04-22 | Univ Cardiff | Chemical compounds |
| WO2000076489A2 (en) | 1999-06-10 | 2000-12-21 | Warner-Lambert Company | Method of inhibiting amyloid protein aggregation and imaging amyloid deposits |
| CA2443285C (en) | 2001-04-05 | 2007-08-21 | Aventis Pharmaceuticals Inc. | Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis |
| PE20030120A1 (es) * | 2001-06-19 | 2003-02-12 | Merck & Co Inc | Sal amina de un antagonista de receptor de integrin |
| DE10129703A1 (de) | 2001-06-22 | 2003-01-02 | Sofotec Gmbh & Co Kg | Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren |
| WO2003006424A1 (en) * | 2001-07-10 | 2003-01-23 | 4Sc Ag | Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| US7258118B2 (en) * | 2002-01-24 | 2007-08-21 | Sofotec Gmbh & Co, Kg | Pharmaceutical powder cartridge, and inhaler equipped with same |
| DE10202940A1 (de) | 2002-01-24 | 2003-07-31 | Sofotec Gmbh & Co Kg | Patrone für einen Pulverinhalator |
| AR042206A1 (es) | 2002-11-26 | 2005-06-15 | Novartis Ag | Acidos fenilaceticos y derivados |
| WO2004056747A1 (en) * | 2002-12-23 | 2004-07-08 | 4Sc Ag | Dhodh-inhibitors and method for their identification |
| WO2004056746A1 (en) | 2002-12-23 | 2004-07-08 | 4Sc Ag | Cycloalkene dicarboxylic acid compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| SE0400234D0 (sv) * | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New compounds, methods for their preparation and use thereof |
| EP1763346A4 (en) | 2004-05-21 | 2009-03-04 | Uab Research Foundation | COMPOSITION AND METHODS RELATING TO INHIBITORS OF PYRIMIDINE SYNTHESIS |
| WO2006022442A1 (ja) | 2004-08-24 | 2006-03-02 | Santen Pharmaceutical Co., Ltd. | ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体 |
| JP2008517059A (ja) | 2004-10-19 | 2008-05-22 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | 炎症性腸疾患を治療するための（ｚ）−２−シアノ−３−ヒドロキシ−ブタ−２−エン酸−（４’−トリフルオロメチルフェニル）−アミドの使用 |
| ES2265276B1 (es) | 2005-05-20 | 2008-02-01 | Laboratorios Almirall S.A. | Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico. |
| PE20120395A1 (es) | 2006-12-04 | 2012-05-23 | Bayer Ip Gmbh | Sal de potasio cristalina de analogos de lipoxina a4 |
| ES2319596B1 (es) * | 2006-12-22 | 2010-02-08 | Laboratorios Almirall S.A. | Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico. |
| ES2366000T3 (es) * | 2007-02-06 | 2011-10-14 | Chelsea Therapeutics, Inc. | Nuevos compuestos, métodos para su preparación y uso de los mismos. |
| UY31272A1 (es) | 2007-08-10 | 2009-01-30 | Almirall Lab | Nuevos derivados de ácido azabifenilaminobenzoico |
| EP2210615A1 (en) * | 2009-01-21 | 2010-07-28 | Almirall, S.A. | Combinations comprising methotrexate and DHODH inhibitors |
| EP2239256A1 (en) * | 2009-03-13 | 2010-10-13 | Almirall, S.A. | Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor |
| EP2228367A1 (en) | 2009-03-13 | 2010-09-15 | Almirall, S.A. | Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors |
| EP2230232A1 (en) | 2009-03-13 | 2010-09-22 | Almirall, S.A. | Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as DHODH inhibitors |
| EP2314577A1 (en) * | 2009-10-16 | 2011-04-27 | Almirall, S.A. | Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid |
-
2008
- 2008-06-20 EP EP08382022A patent/EP2135610A1/en not_active Withdrawn
-
2009
- 2009-06-12 UY UY031897A patent/UY31897A1/es not_active Application Discontinuation
- 2009-06-17 TW TW098120322A patent/TWI440462B/zh not_active IP Right Cessation
- 2009-06-18 JP JP2011513952A patent/JP5507551B2/ja not_active Expired - Fee Related
- 2009-06-18 ES ES09765623.5T patent/ES2641168T3/es active Active
- 2009-06-18 RS RS20171054A patent/RS56584B1/sr unknown
- 2009-06-18 US US12/999,698 patent/US8865728B2/en active Active
- 2009-06-18 DK DK09765623.5T patent/DK2296663T3/en active
- 2009-06-18 SI SI200931742T patent/SI2296663T1/sl unknown
- 2009-06-18 PT PT97656235T patent/PT2296663T/pt unknown
- 2009-06-18 PE PE2010001062A patent/PE20110149A1/es active IP Right Grant
- 2009-06-18 HU HUE09765623A patent/HUE036639T2/hu unknown
- 2009-06-18 AR ARP090102209A patent/AR072174A1/es not_active Application Discontinuation
- 2009-06-18 MY MYPI2010006038A patent/MY155249A/en unknown
- 2009-06-18 EA EA201100028A patent/EA020193B1/ru unknown
- 2009-06-18 KR KR1020107027084A patent/KR101675601B1/ko active IP Right Grant
- 2009-06-18 PL PL09765623T patent/PL2296663T3/pl unknown
- 2009-06-18 CN CN200980123300.6A patent/CN102065866B/zh not_active Expired - Fee Related
- 2009-06-18 NZ NZ589089A patent/NZ589089A/xx not_active IP Right Cessation
- 2009-06-18 CA CA2728976A patent/CA2728976C/en active Active
- 2009-06-18 NO NO09765623A patent/NO2296663T3/no unknown
- 2009-06-18 ME MEP-2017-245A patent/ME02903B/me unknown
- 2009-06-18 SG SG10201609515RA patent/SG10201609515RA/en unknown
- 2009-06-18 AU AU2009259625A patent/AU2009259625B2/en not_active Ceased
- 2009-06-18 BR BRPI0909995A patent/BRPI0909995A2/pt not_active Application Discontinuation
- 2009-06-18 LT LTEP09765623.5T patent/LT2296663T/lt unknown
- 2009-06-18 EP EP09765623.5A patent/EP2296663B1/en active Active
- 2009-06-18 MX MX2010013409A patent/MX2010013409A/es unknown
- 2009-06-18 UA UAA201100428A patent/UA114388C2/uk unknown
- 2009-06-18 WO PCT/EP2009/004404 patent/WO2009153043A1/en active Application Filing
- 2009-06-18 SG SG2013030663A patent/SG189810A1/en unknown
-
2010
- 2010-11-10 ZA ZA2010/08041A patent/ZA201008041B/en unknown
- 2010-11-11 IL IL209267A patent/IL209267A/en active IP Right Grant
- 2010-11-16 CO CO10143337A patent/CO6321267A2/es active IP Right Grant
- 2010-12-06 CL CL2010001359A patent/CL2010001359A1/es unknown
-
2017
- 2017-10-31 HR HRP20171667TT patent/HRP20171667T1/hr unknown
- 2017-11-08 CY CY20171101170T patent/CY1119643T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR072174A1 (es) | Combinaciones que comprenden inhibidores de dhodh (dihidroorotato deshidrogenasa) y metotrexato. uso. producto. kit. metodo. | |
| AR075036A1 (es) | Combinaciones que comprenden metotrexato e inhibidores de dhodh | |
| RU2009127847A (ru) | Производные аминоникотиновой кислоты и изоникотиновой кислоты как ингибиторы дгодг (дигидрооротатдегидрогеназы) | |
| CN103097353B (zh) | 免疫调节剂和抗炎化合物 | |
| HRP20120115T1 (hr) | Derivati azabifenil aminobenzojeve kiseline kao inhibitori dhodh | |
| US9834545B2 (en) | Modulators of chemokine receptors | |
| Tanimoto et al. | Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo | |
| Johnson et al. | Discovery and optimization of a series of quinazolinone-derived antagonists of CXCR3 | |
| JP2016515119A5 (es) | ||
| JP2019506380A5 (es) | ||
| ZA200406937B (en) | Derivatives of 4-(imidazol-5-YL)-2-(4-sulfoanilino) pyrimidine with CDK inhibitory activity. | |
| MXPA04007018A (es) | Quinazolina(di)onas para control de plagas de invertebrados. | |
| JP2013533279A5 (es) | ||
| El‐Gamal et al. | FMS kinase inhibitors: current status and future prospects | |
| MX2007000051A (es) | Derivados de pirimidina fusionados y composiciones de los mismos como moduladores del receptor cxcr3, utiles en la prevencion y tratamiento de trastornos y enfermedades inflamatorias e inmunoregulatorias. | |
| AR049138A1 (es) | Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis | |
| BRPI0409921A (pt) | derivados de éster e amida de ácido 2-cianopropanóico e métodos de seu uso | |
| Savateev et al. | Azoloazines as A2a receptor antagonists. Structure–activity relationship | |
| NZ594493A (en) | Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as dhodh inhibitors | |
| CO6420336A2 (es) | Sal de sodio de ácido 5-ciclopropil-2-{[2-(2,6-difluorofenil)pirimidin-5-il]amino}benzoico como inhibidor de dhodh | |
| CN101460487A (zh) | 3-(1，3-苯并间二氧杂环戊烯- 5-基)-6-(4-环丙基哌嗪-1-基)-哒嗪、其盐和溶剂合物及其作为组胺h3受体拮抗剂的用途 | |
| JP2017502967A5 (es) | ||
| JP2015501327A5 (es) | ||
| CR20210375A (es) | Formas cristalinas y formas de sal de un inhibidor de cinasa | |
| ATE461192T1 (de) | Chinoloncarbonsäureverbindungen mit 5-ht4- rezeptoragonistischer wirkung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |